OHR Pharmaceutical Inc (NASDAQ:OHRP), an ophthalmology research and development company, presented additional positive data from the Phase 2 IMPACT study evaluating OHR-102 (Squalamine lactate …
Brean Capital analyst Jonathan Aschoff came out today with some commentary on OHR Pharmaceutical Inc (NASDAQ:OHRP), after the company reported initial, encouraging data for the treatment of …
OHR Pharmaceutical Inc (NASDAQ:OHRP) shares have taken off, adding 44.05% to trade at $3.
Groupon Inc (NASDAQ:GRPN) shares rose 3.3% in pre-market trading to $5.
OHR Pharmaceutical Inc (NASDAQ:OHRP) shares plunged nearly 70% today after the company announced topline results from its exploratory phase II IMPACT study testing OHR-102 in combination with Lucentis …
In a research note published after market close today, Chardan Capital analyst Gbola Amusa maintained a Neutral rating on OHR Pharmaceutical Inc (NASDAQ:OHRP) and reduced …
In a research report released Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on OHR Pharmaceutical Inc (NASDAQ:OHRP) with a $34 …
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on OHR Pharmaceutical (NASDAQ:OHRP) with a $34 price target, …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on OHR Pharmaceutical Inc (NASDAQ:OHRP) with a $34 …
